We have shown previously that low doses of selective sigma (cr)-receptor ligands potentiate the excitatory response of pyramidal neurons to NMDA in the CA, region of the dorsal hippocampus in the rat. Because progesterone competitively displaces the binding of the ligand N-[3H]allyl-normetazocine (SKF-10,047), the present studies were undertaken to determine in viva the effect of neuroactive steroids on NMDAinduced excitation of rat CA, pyramidal neurons. Low doses of dehydroepiandrosterone (DHEA) potentiated the NMDA response selectively and dose-dependently.
We have shown previously that low doses of selective sigma (cr)-receptor ligands potentiate the excitatory response of pyramidal neurons to NMDA in the CA, region of the dorsal hippocampus in the rat. Because progesterone competitively displaces the binding of the ligand N-[3H]allyl-normetazocine 047) , the present studies were undertaken to determine in viva the effect of neuroactive steroids on NMDAinduced excitation of rat CA, pyramidal neurons. Low doses of dehydroepiandrosterone (DHEA) potentiated the NMDA response selectively and dose-dependently.
The effect of DHEA was reversed by the selective v antagonist N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)-ethylamine monohydrochloride (NE-100) and by haloperidol, but not by spiperone. Progesterone had no effect by itself but reversed, at low doses, the potentiation of the NMDA response induced by DHEA as well as those induced by nonsteroidal u ligands. Neither pregnenolone nor pregnenolone sulfate had any effect on the NMDA response-nor did they antagonize the potentiation of the NMDA response induced by DHEA and by nonsteroidal IJ ligands. A pet-tussis toxin pretreatment, which inactivates G,,,-proteins, abolished the potentiating effects of DHEA. Ovariectomy enhanced the potentiation of the NMDA response by the nonsteroidal CT ligand di(2-tolyl)guanidine (DTG). There was a reciprocal occlusion of the effects of DHEA and DTG; DTG did not potentiate the NMDA response further after DHEA, and DHEA did not do so after DTG. These results suggest that some neuroactive steroids modulate the NMDA response via g receptors.
Key words: neurosteroids; hippocampus; electrophysiology; ovariectomy; haloperidol; DTG Sigma ((7) receptors are present in high density in the CNS (Walker et al., 1990) and in peripheral organs, with a particularly high density in the ovaries (Wolfe et al., 1989) . Many psychotropic drugs such as antipsychotics and antidepressants have high affinity for v receptors (Su, 1982; Schmidt et al., 1989 ; Snyder and Largent, 1%'); ltzhak and Kassim, 1990; Ferris et al., 1991) . Several steroids, progesterone in particular, also bind with high affinity to (7 receptors (Su et al., 1988) .
Previous studies have demonstrated that low doses of selective CT ligands, such as di(2-tolyl)guanidine (DTG) (Weber et al., 1986) , I-benzylspiro [ 1,2,3,4-tetrahydro-aphthalene-1,4-piperidine] (L-687,384) (Middlemiss ct al., 1991; Barnes et al., 1992) , (+)N-cyclopropylmethyl-N-methyl-l ,4-diphenyl-1-ethyl-butyl-3-N-I-ylamine hydrochloride (JO-1784) (Roman et al., 19Y0) , and (+)pentazocine (Steinfels et al., 1988) selectively potentiate the response of rat CA, dorsal hippocampus pyramidal neurons to microiontophoretic applications of NMDA (Monnet et al., 1990 (Monnet et al., , 1992 Martin et al., 1992; Walker and Hunter, 1994) . This effect is reversed by other u ligands such as haloperidol, (+)3-hydroxyphenyl-N-i-( 1 -propyl)piperidine
[also known as (+)3-PPP], and cr-(4-fluorc~phenyl)-4-(5-flu~~ro-2-pyrimidinyl)-l-piper~ine butanol (BMY-14802) (Largent et al., 1984; Tam and Cook, 1984 a\\i\tancc. Dekleva, 1987) , but not by spiperone, which has a binding profile similar to that of haloperidol except for its low affinity for v receptors (Monnet et al., 1990, 19Y2 ). We also have tested recently the novel and very selective (T ligand N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)-ethylamine monohydrochloride (NE-100) (Okuyama et al., 1993) . It proved extremely potent in blocking or reversing the potentiation of the NMDA response induced by v ligands such as DTG (Debonnel et al., 1995a) . Therefore, g ligands acting like DTG have been denoted tentatively cr "agonists," and (r ligands acting like haloperidol have been denoted "antagonists" (Monnet et al., 1990) . These data and several other reports from other laboratories using biochemical, neuroendocrinological, and behavioral models suggest the existence of a functional interaction between (T and NMDA receptors, although the exact mechanism is not understood fully (for review, see Dcbonncl, lYY3).
There are several types of (T receptors; those classified as (r, and cr, have been characterized most extensively (Quirion et al., 1992) . The most commonly used g ligands, including haloperidol and DTG, do not discriminate between CT, and (r7 receptors (Quirion et al., 1992) , whereas drugs such as (+)pentazocine, JO-1784, L-687,384, N-allyl-normetazocine [( +)SKF-100471, and NE-100 are selective for g, receptors (Quirion et al., 1992; Chaki et al., 1994) . However, recent data obtained in our laboratory have shown that pertussis toxin (PTX) pretreatment abolishes the potentiation induced by JO-1784, but not that induced by (+)pentazocine (Monnet et al., 1994) , which suggests that these two (r ligands act on different u-receptor subtypes. Moreover, the injection of colchicine in the dentate gyrus, which destroys the mossy fiber system (a major afference to CA, pyramidal neurons), abolishes the potentiation of the NMDA response induced by DTG and JO-1784, but not that of (+)pentazocine, suggesting that the subtype of u receptors on which DTG and JO-1784 are acting is located prcsynaptically on the mossy-fiber terminal, whereas the subtype of u receptors on which (+)pentazocine is acting is located postsynaptically (Debonnel et al., 199%) .
Several reports have shown that progesterone acts as a competitive inhibitor of [3H](+) SKF-10047 or ['H]haloperidol (Su et al., 1988; iLk&nn et al., 19Y4; Yamada et al., 1994; Ramamoorthy et al., 1995) at (r receptors and have prompted us to assess the potential agonistic or antagonistic properties of progesterone, dehydroepiandrosterone (DHEA), and other neuroactive steroids (Paul and Purdy, 1992) The duration of the microiontophorctic applications and the intensity of the currents used also wcrc stored on-line. The elfccts of their applications on pyramidal neuron firing activity were expressed as the number of spikes generated per nanocoulomb (nC: I nC is the charge generated by 1 nA applied for 1 set). After a neuron was isolated, it was recorded for a period of at least 20 min before any drug was injected.
The recording was stored on-line without interruption for the duration of the experiment. Five to six applications of each excitatory substance (NMDA. QUIS. and ACh) wcrc carried out before the drugs studied wcrc injcctcd or applied microiontophoretically.
The effects of drugs studied appcarcd within a period of 10 min after their intravenous injection. The calculations wcrc carried out when the maximal effect of the drug was achieved (within the first 20 min). At the end of the experiment, a -27 FA current was passed through the central barrel for 20 min to deposit Fast Green FCF for subscqucnt histological verification of recording sites. Esl,crinrerzral se+s. Neuroactive steroids wcrc prcparcd in ;I solution of 40% polyethylene glycol. The (r ligands were prepared in physiological saline, and they were administered via a lateral tail vein. In all cxpcrimental series, only one dose of each drug was administered to one rat while recording from one neuron. In the first series of experiments, several doses of each drug wcrc tested to generate dose-response ctnvcs. Progesterone, DHEA, prcgnenolonc, and pregnenolone sulfate wcrc tested at doses ranging from I Kg to 2 mgikg. In the second series, progesterone (20 pg/kg, iv.) was tested as an antagonist of the potcntiation of the NMDA response induced by the previous administration of a low dose of DHEA or of the following nonstcroid rr ligands: DTG I pg/kg, i.v.; L-(,X7,384 I kg/kg, iv.; JO-17X4 5 &kg, iv.; (+)pentazocine IO &kg, iv. In the third series, rats were pretrcatcd with 21 local injection of PTX to assess the possible involvement of (r rcccptors coupled with G,,,,-proteins in the potentiation of the neuronat response to NMDA bv neuroactive steroids. In the fourth series, we have examined the possibility 01 a reciprocal occlusion of the cffccts of DTG and DIIEA. In the final scrics. the degree of the potcntiation of the NMDA response induced by DTG (I &kg, iv.) was measured in male rats, in female rats at days I and .i of the menstrual cycle, and in OVX rats I4 d after the surgery. Crrk~irkrtions.
The The intravenous injection of the vehicle (40% polyethylene glycol), used for preparing the solutions of neuroactive steroids, affected neither the spontaneous firing activity of dorsal hippocampus CA, pyramidal neurons nor their response to NMDA, QUIS, and ACh.
Effects of DHEA
The intravenous administration of 100 pg/kg DHEA induced a twofold increase of the response of dorsal hippocampal CA3 pyramidal neurons to microiontophoretic applications of NMDA without affecting their response to QUIS (Fig. 1A) . The effect of DHEA was dose-dependent, and a maximal potentiation was obtained at a dose of 500 pg/kg, i.v. (Fig. 1B) . No additional 
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tiringrate histogram of a CA, dorsal hippocampus pyramidal neuron illustrating the effect of microiontophoretic applications of NMDA, QUIS, and AC% before and after the administration of DTG (arrows) and after the administration of progesterone. Time scale applies to the three traces. potentiation was obtained by increasing the dose of DHEA up to 2 mg/kg, i.v. (Fig. 1) . This enhancing effect of DHEA lasted for at least 40 min. The potentiation of the NMDA response by DHEA was reversed by haloperidol (20 pg/kg, i.v.; Fig. lC) , but not by spiperone (20 kg/kg, i.v.; Fig. 1D ) and not by the intravenous administration of saline (Fig. 1E ). Moreover, NE-100, a novel selective v antagonist (Okuyama et al., 1993) at a dose of 25 pg/kg, i.v., also suppressed the potentiation of the NMDA response induced by DHEA (Fig. 1F) .
Effects of progesterone At doses ranging from 1 to 2000 pg/kg, i.v., progesterone did not affect the neuronal response induced by microiontophoretic applications of NMDA (Fig. 2&?) , QUIS, or ACh. However, progesterone, at a dose of 20 kg/kg, i.v., prevented and reversed the Fig. 2C ). To investigate the possibility that this effect of progesterone could be mediated via c receptors, low doses of the selective u ligands DTG (1 pg/kg, i.v.; Fig. 3 ), L-687,384 (1 pg/kg, i.v.), JO-1784 (5 pg/kg, i.v.), and (+)pentazocine (10 pg/kg, i.v.) were administered to naive rats as illustrated for DTG in Figure  3 . Progesterone (20 pg/kg, i.v.; Fig. 4A-D) reversed the potentiation induced by the nonsteroidal v ligands. Haloperidol (20 pg/kg, i.v.; Fig. 4E ), but not spiperone (20 pg/kg, i.v.; Fig. 4F) , also reversed the effect of DTG as reported previously (Monnet et al., 1990; Bergeron et al., 1993) .
Effects of pregnenolone and pregnenolone sulfate
The effects of pregnenolone and pregnenolone sulfate were assessed in the same paradigm. At doses ranging from 1 to 2000 pg/kg, i.v., these two neuroactive steroids did not modify NMDA-, QUIS-, or ACh-induced neuronal responses. The efficacy of these two neuroactive steroids in reversing the potentiation of the NMDA response induced by a previous administration of DHEA (100 Fg/kg, i.v.), as well as by other nonsteroidal (T agonists, also was tested. Pregnenolone and pregnenolone sulfate neither reversed nor prevented the potentiation of the NMDA response induced by DHEA (Fig. 5A,B) . Similarly, neither pregnenolone nor pregnenolone sulfate suppressed the potentiation of the NMDA response induced by the nonsteroidal cr agonists DTG (1 Fg/kg, i.v.; Fig. . 
Effect of coadministration of DHEA and DTG
To test the possibility that DHEA and nonsteroidal rr ligands both activate (T receptors, we have examined the possibility of a reciprocal occlusion of the effects of DHEA and DTG. The microiontophoretic applications of DTG (20 nA) produced, as observed previously (Monnet et al., 1990; Bergeron et al., 1995a) , a twofold increase in the neuronal response to NMDA. The injection of DHEA at 200 pg/kg, i.v., failed to elicit an increase in NMDA response. Conversely, the intravenous administration of DHEA at 200 pg/kg also induced a threefold increase in the neuronal response to NMDA, and the subsequent microiontophoretic applications of DTG (20 nA) failed to elicit an increase in NMDA response (Fig. 6) .
Effect of PTX pretreatment on the potentiation induced by DHEA PTX, which inactivates G,,-proteins via ADP ribosylation, was used to assess the possible involvement of these proteins in the modulation of NMDA-induced neuronal activation in the CA, region of the rat dorsal hippocampus by DHEA. The in viva PTX pretreatment affected neither the spontaneous firing activity of CA, pyramidal neurons nor their responsiveness to NMDA, QUIS, or ACh, which is in agreement with previous data (Monnet et al., 1994) . DHEA, at a dose of 250 kg/kg, i.v. (a dose producing a more than twofold increase of the NMDA response in control rats), failed to produce any potentiation of the NMDA response in PTX-pretreated rats (Fig. 7A,B) . We have reported previously that PTX pretreatment abolishes the potentiation of the NMDA response by JO-1784, but not that induced by (+)pentazocine, and this effect of (+)pentazocine was still reversed by a low dose of haloperidol (Monnet et al., 1994) . In the present series, the potentiating effect of (+)pentazocine (10 pg/kg, i.v.) was still present in PTX-treated rats; this effect of (+)pentazocine was reversed readily by progesterone (20 pg/kg, i.v.; Fig. 7C,D) . Effect of OVX on the potentiation induced by DTG In the final series of experiments, we measured the magnitude of the potentiation induced by DTG (I pg/kg, i.v.) in male rats and in female rats at days 1 and 3 of the menstrual cycle, as well as 2 weeks after OVX. As shown in Figure 8 , no significant difference was found between the degrees of potentiation induced by DTG in male rats and non-OVX female rats at either day I or day 3 of the menstrual cycle. In these three groups, the potentiation of the NMDA response induced by DTG was suppressed completely by progesterone (20 pg/kg, i.v.) and by haloperidol (20 pg/kg, i.v.; Fig. 8 ). However, the degree of the potentiation produced by DTG in OVX rats was significantly greater than that observed in the three other groups (Fig. 8) . Moreover, in OVX rats, one dose of 20 pg/kg, i.v., progesterone reversed DTG-induced potentiation only partially. Such a dose of progesterone completely reversed the effect of DTG in male and non-OVX female rats (Fig. 8) . In OVX rats, a second dose of 20 pg/kg, i.v., progesterone or a subsequent injection of 20 pg/kg, i.v., haloperidol was required to obtain a complete suppression of the potentiation of the NMDA response induced by DTG (Fig. 80) .
DISCUSSION
The present results indicate that DHEA at very low doses selectively potentiates, in a dose-dependent manner, the neuronal response to microiontophoretic applications of NMDA onto pyramidal neurons in the CA, region of the rat dorsal hippocampus (Fig. 1) . This potentiation is reversed by NE-100 and haloperidol, but not by spiperone or saline (Fig. I) . Progesterone, at doses ranging from 1 pg/kg to 2 mgikg, iv., does not modify the NMDA response by itself, but suppresses at the very low dose of 20 pgikg, i.v., potentiation of the neuronal response to NMDA induced by DHEA as well as by several nonsteroidal (r ligands (Figs. 2-4 ). Pregnenolone and pregnenolone sulfate neither modify the NMDA response nor prevent or suppress the potcntiation of the NMDA response induced by DHEA and by nonsteroidal (T agonists (Fig. 5) .
Several interactions between the NMDA-receptor complex and some neuroactive steroids have been documented (Wu et al., 1991; Irwin et al., 1992; Maione et al., 1992; Bowlby, 1993 tergic activation of the NMDA receptor (Irwin et al., 1992) . In this preparation, NMDA-receptor activation produces a greater inward current of CaZ+ in the presence of pregnenolone sulfate; this effect has been attributed to a direct action of the steroid on the NMDA-receptor complex (Bowlby, 1993) . Pregnenolone sulfate also enhances NMDA-gated currents in spinal cord neurons and increases significantly the proconvulsant activity of NMDA (Maionc et al., 1992) . The mechanisms whereby neurosteroids affect glutamatergic transmission are not elucidated completely. A growing body of evidence suggests that many neuroactive steroids can rapidly alter the excitability of neurons via a modulation of GABA, receptors acting as agonists (e.g., pregnenolone sulfate and estrogen) or as antagonists (e.g., progesterone) (Majewska et al., 1986 (Majewska et al., , 1990 Lambert et al., 1987; Majewska and Schwartz, 1987; Mienville and Vicini, 1989; Morrow et al., 1990; Wu et al., 1990; Purdy et al., 1991) . The interactions observed in the present study are unlikely to be related to a GABA,-receptor modulation, because pregnenolone and pregnenolone sulfate were inactive in our model (Fig. S) , whereas these two neuroactive steroids are among the most active in paradigms involving the GABA, receptors (for review, see Baulicu, 1991) . Other mechanisms also have been suggested, such as the existence of steroid recognition sites on the NMDA-receptor complex itself (Irwin et al., 1992) . However, such a mechanism could not account for the effect of progesterone in our paradigm, because it did not modify the NMDA response. Nonetheless, the possibility of a downstream action of progesterone at the level of effector mechanisms triggered by a-receptor activation cannot be ruled out at present.
Several observations suggest that the selective modulation of the NMDA response by the neuroactive steroids reported here is mediated via cr receptors. First, the potentiation induced by DHEA is suppressed by haloperidol, but not by spiperone (Fig.  1C) . Indeed, spiperone binds with high affinity to dopaminergic, a,-adrenergic, and serotonergic receptors, as does haloperidol (Burt et al., 1977; Clark et al., 1985) , but it has a low affinity for a-binding sites (Su, 1982; Tam and Cook, lY84; Weber et al., 1986; Steinfels et al., 1989) . Second, a low dose (25 pgikg, i.v.) of the selective cr antagonist NE-100 also suppresses the potentiation of the NMDA response induced by DHEA (Fig. lF) , as well as the potentiation induced by nonsteroidal (T ligands (Debonncl et al., 1995a,b) . Third, low doses of progesterone prevent and suppress not only the potentiating effect of DHEA, but also those induced by the selective nonsteroidal (T ligands DTG, 50-1784, L-687384, and (+)pentazocine (Figs. 2-4) . Fourth, pregnenolone and pregnenolone sulfate, which have low affinity for (r receptors (Su et al., 1988) , neither prevent nor suppress the potentiation of the NMDA response by DHEA and by the nonsteroidal (r agonists even when administered at doses up to 2 mgikg, i.v. Moreover, our hypothesis is supported by a recent report showing that neuroactive steroids modulate, via CT receptors, the [jH]norepinephrine release evoked by NMDA in the rat hippocampus (Monnet et al., 1995) .
After the intravenous administration of DHEA (200 pg/kg), microiontophoretic application of DTG (20 nA) was ineffective in enhancing the NMDA response further (Fig. 6) . Moreover, when DTG was applied microiontophoretically (20 nA), the intravenous injection of DHEA was ineffective in enhancing the NMDA response further (Fig. 6) We have reported previously that several nonsteroidal (r ligands exhibit a bell-shaped dose-response curve (Bergeron et al., 1993 (Bergeron et al., , 1995a . This effect does not appear to be attributable to a rapid desensitization of u receptors but, rather, to the sequential activation of distinct subtypes of (r receptors (Bergeron et al., 199Sa) . DHEA does not present such a bell-shaped dose-response curve, but plateaus at doses higher than 500 pg/kg, iv. (Fig. 1B) . This suggests that DHEA acts on only one subtype of (T receptor. The facts that the potcntiating effect of DHEA was suppressed by PTX pretreatment and by the selective (7, antagonist NE-100 suggest that the effect of DHEA is mediated via cr, receptors. Moreover, after the inactivation of G,,,-proteins by a PTX pretreatment, the intravenous administration of DHEA fails to modify the neuronal response to NMDA (Fig. 6) suggesting that the potentiating effect of DHEA on the NMDA response results from the activation of U, receptors coupled to G,,,,-proteins. We have reported J. Neurosci., February 1, 1996 , 16(3):1193 -1202 1201 previously that PTX pretreatment does not affect the potcntiation of the NMDA response induced by (+)pentazocine, but suppresses those induced by DTG and JO-1784 (Monnet et al., 1994) . Thus, it appears that DHEA activates a different (r, receptor from that activated by (+)pentazocine.
Interestingly, progesterone reverses the persistent potentiating effect of (+)pentazocine in PTX-rats (Fig. hD) , as is the case for haloperidol (Monnct et al., 1994) which suggests that, in contrast to DHEA, progcstcronc acts on more than one subtype of m receptor. The fact that the potentiation of NMDA-induced neuronal response obscrvcd it? vitro by Bowlby (1993) with pregnenolonc sulfate was not suppressed after a PTX pretreatment constitutes another argument suggesting that pregnenolone sulfate (in his paradigm) and DHEA (in our model) modulate the NMDA response via distinct mechanisms.
No significant difference was found in the degrees of potcntiation of the NMDA response induced by DTG in male and non-OVX female rats. However, a significant increase in the magnitude of this potentiation was observed in OVX rats (Fig. 7) . This may be attributable, at least in part, to the fact that OVX decreases the levels of progesterone.
Indeed, because this steroid appears to be a potent antagonist of (r receptors, the low levels of progesterone in the OVX rats may account for the greater potentiation of the NMDA response by DTG. This would imply that the NMDA response is dampened tonically by progesterone. In keeping with this interpretation, there is a marked reduction in the effectiveness of DTG in potentiating the NMDA response during late pregnancy (Bergeron et al., 1995b) , a period during which progesterone levels are very high (Schwarz et al., 1989) . Given the very low doses of progesterone administered in the present study, one can assume that its effect is of physiological relevance.
In conclusion, DHEA and progesterone appear to act as potent modulators at g receptors. Because the prototypical (T ligand SKF-10047 produces marked neuropsychological perturbations in humans, the well known neuropsychological effects of neuroactive steroids in the course of the menstrual cycle or pregnancy might be related, at least in part, to alterations of neuronal responsiveness to NMDA via a modulation of u-receptor function.
